NeoGenomics
NEO | NASDAQ
$15.41
-$0.61 (-3.81%)
At close: Nov 16, 2026, 4:00 PM ET
$15.41
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
NeoGenomics Company Profile
Company profile explainedCompany Profile
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Key Executives
| Name | Position |
|---|---|
| Anthony Zook | Chief Executive Officer & Director |
| Warren Stone | President & Chief Operating Officer |
| Abhishek Jain | Executive VP & CFO |
| Alicia Olivo | Executive Officer |
| Andrew A. Lukowiak | Chief Innovation Officer |
| Andrew Frederick Brackmann | Vice President of Investor Relations |
| Clarence Cooper | Vice President of Compliance & Privacy |
| Elizabeth A. Floegel | Chief Digital & Information Officer |
| Gary Passman | Chief People & Culture Officer |
| Gregory D. Aunan | Senior Vice President & Chief Accounting Officer |
| Kristi McKeown | Chief Commercial Officer |
| Priya Vedaraman | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | S-8 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 4 | Filing |
NeoGenomics
| Country | United States |
| IPO Date | Mar 16, 2004 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,500 |
| CEO | Anthony Zook |
Contact Details
9490 NeoGenomics Way Fort Myers,
Florida 33912 United States
Stock Details
| Ticker Symbol | NEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001077183 |
| CUSIP Number | 64049M209 |
| ISIN Number | US64049M2098 |
| SIC Code | 8734 |
Recent News
- 3 days ago / businesswire.comBetter Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans Channel
- 5 days ago / globenewswire.comFDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
- 5 days ago / globenewswire.comNeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
- 11 days ago / businesswire.comNeoGenomics to Participate in Upcoming Investor Conferences
- 15 days ago / globenewswire.comNeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
- 18 days ago / prnewswire.comNEO Battery Reports Fiscal Year 2027 Second Quarter Results
- 19 days ago / marketbeat.comWhat NeoGenomics (NEO) Said on Its Q3 Earnings Call
- 1 month ago / newsfilecorp.comNeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
- 1 month ago / globenewswire.comNeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
- 1 month ago / globenewswire.comNeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
Add to Watchlist
Select watchlists to add or remove NEO